nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Langer, Corey J., Kim, Edward S., Anderson, Eric C., Jotte, Robert M., Modiano, Manuel, Haggstrom, Daniel E., Socoteanu, Matei P., Smith, David A., Dakhil, Christopher, Konduri, Kartik, Berry, Tymara, Ong, Teng J., Sanford, Alexandra, Amiri, Katayoun, Goldman, Jonathan W., Weiss, Jared
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066531/
https://www.ncbi.nlm.nih.gov/pubmed/30087851
http://dx.doi.org/10.3389/fonc.2018.00262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066531/
https://www.ncbi.nlm.nih.gov/pubmed/30087851
http://dx.doi.org/10.3389/fonc.2018.00262

Ejemplares similares